secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2026-08-10T11:00:07+00:00
Accession:  0001193125-26-341187
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru reports Q3 FY2026 net loss $7.0M; PLATEAU trial fully enrolled with 239 patients
--------------------------------------------------------------------------------

- Q3 net loss $7.0M ($0.30/share) vs $7.3M ($0.50/share) prior year; operating loss $7.7M.
- Phase 2b PLATEAU fully enrolled with 239 patients (target 200); interim analysis Q1 2027, final topline Q4 2027.
- USPTO notice of allowance for enobosarm+semaglutide patent; protection until at least Oct 2044.
- Clinical supply agreement with Novo Nordisk for PLATEAU trial announced June 2026.
- Cash $23.9M at June 30, 2026 vs $15.8M at Sept 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/0001193125-26-341187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/d123580d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-341187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer